Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail by Neesgaard, Bastian et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood
spots sent by regular mail








Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Neesgaard, B., Ruhwald, M., Krarup, H. B., & Weis, N. (2018). Determination of anti-HCV and quantification of
HCV-RNA and IP-10 from dried blood spots sent by regular mail. PLoS ONE, 13(7), [e0201629].
https://doi.org/10.1371/journal.pone.0201629
Download date: 03. Feb. 2020
RESEARCH ARTICLE
Determination of anti-HCV and quantification
of HCV-RNA and IP-10 from dried blood spots
sent by regular mail
Bastian Neesgaard1*, Morten Ruhwald2, Henrik B. Krarup3, Nina Weis1,4
1 Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark, 2 Center for
Vaccine Research, Section of Human Immunology, Statens Serum Institut, Copenhagen, Denmark,
3 Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark,





With the introduction of direct acting antivirals, treatment of hepatitis C virus (HCV) in hard-
to-reach populations is now feasible. Therefore, new cost-effective and reliable test meth-
ods are needed. Determination of HCV antibodies and HCV-RNA from dried blood spots
samples could represent one such method. Here we examined whether anti-HCV could be
detected—and HCV-RNA quantified—from dried blood spots, sent by regular mail. We also
investigated, if IP-10 determined from dried blood spots correlated with fibrosis progression
appraised by transient elastography.
Method
Forty chronic HCV infected patients were consecutively enrolled. At baseline and after six
months, dried blood spots were prepared from blood collected by venous puncture, dried for
4–6 hours, then stored in gas-impermeable plastic bags with a desiccator, before being sent
by regular mail. At each visit, approximately six months apart, paired venous samples was
obtained and analyzed for anti-HCV, HCV-RNA and IP-10.
Results
Anti-HCV was found in 66/67 of the dried blood spots. Sixty-six paired samples were avail-
able for HCV-RNA analysis. A statistically significant correlation was found between log
HCV-RNA concentrations in plasma, and log HCV-RNA obtained from (P < 0.0001, Pear-
son’s R 0.6788, R2 0.4607). HCV-RNA, derived from DBS samples, was lower than the cor-
responding plasma concentration, reflected by a Bland-Altman bias of 3 with SD of bias ±
0.6472. We found no correlation between IP-10 and fibrosis progression.
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Conclusions
We identified anti-HCV in 66/67samples, and quantified IP-10 and HCV-RNA from dried
blood spots, dried at room temperature and sent by regular mail. HCV-RNA concentrations
from the dried blood spots were lower than corresponding plasma values; a probable result
of heparin coated test tubes. We found no correlation between IP-10 and fibrosis progres-
sion. Overall, dried blood spots could be a cost-effective and easy-to-use alternative to stan-
dard tests for the diagnosis of HCV infections.
Introduction
Globally, the prevalence of chronic hepatitis C (CHC), defined as detectable hepatitis C virus
(HCV)-RNA in two consecutive measurements six months or more apart, is estimated to 71
million people [1], with CHC being a leading cause of chronic liver disease [2]. CHC can lead
to liver fibrosis, which may in turn lead to the development of cirrhosis in approximately
5–20% of cases [2–5]. Once cirrhosis occurs, there is a marked increase in the risk of develop-
ing hepatocellular carcinoma [6].
With the introduction of Direct Acting Antivirals (DAAs), treatment regimens are now all-
oral, with shorter duration, higher rates of sustained virological response and fewer adverse
effects. Thus, treatment of populations that have previously been viewed as hard to reach is
now feasible.
With these new treatment possibilities, new cost-effective, easy to perform and reliable
methods are needed to increase the diagnostic rate of HCV infected people in these difficult-
to-reach populations.
Dried blood spots (DBS) could represent such a method. Since their introduction in the
early 1960s, by Dr. Robert Guthrie as a simple screening test for phenylketonuria in newborns
[7], the use of DBS has since been extended to aid in the diagnosis of a wide variety of patho-
gens, including hepatitis A, B and HIV [8, 9]. Detection of HCV-RNA [10–21], anti- HCV [9,
20, 22–25] and determination of HCV genotype (GT) [15, 19, 21] from DBS have also been
investigated. Although HCV-RNA can be detected at levels of 250 IU/mL in DBS [11], this is
still higher than the 50 IU/mL detection limits for plasma samples. Despite findings of a strong
correlation between the detection of HCV-RNA in plasma samples and DBS [21] it remains
unclear if DBS can be used as a valid tool for quantification of the viral load. In addition, it is
unclear how storage, temperature and handling of DBS affect the levels of HCV-RNA.
Recently, within our group, a method to accurately measure interferon γ-induced protein
10 kDa (IP-10) in DBS by ELISA was developed [26]. Also we have recently showed that GT 1
infected patients with cirrhosis have significantly higher levels of IP-10 than patients with no-
or mild fibrosis [27, 28], fully in line with others’ results for HCV GT1 infected patients [29–
33]. Together with the above-mentioned previous findings on HCV-RNA, the implication of
DBS use could hold a promising future for diagnosing HCV infections and surveillance of dis-
ease activity. However, this is dependent on antibodies and HCV-RNA stability on DBS, in
order to be successfully analyzed after being sent / shipped from the patient to the laboratory
facilities.
The primary objectives of this study were to examine if anti-HCV antibodies could be
detected and HCV-RNA and IP-10 quantified in DBS samples sent by regular mail, and how
the HCV-RNA value from these samples related to the HCV-RNA value in paired plasma
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samples. As a secondary objective, IP-10 values in DBS were correlated to paired plasma sam-




This study was approved by The Regional Committee on Biomedical Research Ethics (H-3-
2013-152). After oral and written information about the study all patients gave informed con-
sent in writing.
Patients
Patients’ 18 years of age were consecutively enrolled from the outpatient clinic, Department
of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark. Individuals
were considered for inclusion if they had CHC (detectable HCV-RNA in two consecutive mea-
surements six months or more apart). Patients were excluded if they were co-infected with
HIV or HBV, had alcohol dependency- (regular intake of 75 g/day), ongoing intravenous
drug use, had been treated with immunosuppressant drugs or had received treatment for CHC
within the last six months.
At baseline, we registered patients’ gender, age, ethnicity, anti-HCV, HCV-RNA, HCV-
genotype, IP-10, ALT levels and Transient Elastography (TE) score.
Sample collection and preparation
Preparation of DBS—And plasma samples. On the day of enrollment, DBS samples for
IP 10 analyses were prepared, as described in detail elsewhere [26]. In brief, the skin on a ran-
dom fingertip was pierced by a small finger prick, after the skin had been disinfected by a stan-
dard ethanol swipe. Blood was then added to a filter paper (903 Protein Saver™ cards,
Whatman) in duplicate. After 4–6 hours’ drying on the lab bench DBS samples were stored in
a gas-impermeable plastic bag with a desiccator and placed in another gas-impermeable plastic
bag. The samples were then placed in a standard envelope for transferring biological material
and sent by regular mail to the Department of Infectious Diseases, Copenhagen University
Hospital, Hvidovre, Denmark. On arrival, the filter paper containing the IP-10 samples were
frozen at -20 OC until time of analysis. Denmark is located in the temperate climate zone. Dur-
ing the study period, the average temperature therefore was between 0.5–16˚C. The average
transit time in mail was 4 days.
At the same day as DBS preparation, a venous blood sample was drawn, using a 4 mL Li-
Hep coated tube containing a separation gel. Forty μl blood (per spot) were transferred in
duplicates to another piece of filter paper, intended for HCV-RNA quantification and anti-
body determination. Hereafter, the plasma was separated from the whole blood by centrifuge
and 0.5 mL were transferred to a cryotube, and frozen at -20 OC until time of analysis for
plasma IP-10 levels. The filter paper containing the microbiological samples was dried, packed
and sent, in the same manner as the IP-10 samples, however, on arrival these were frozen at
-80 OC. At the patient’s next routine visit, six months later, this procedure was repeated.
Transient elastography. For liver stiffness measurements we used Fibroscan1 (Echo-
sens, Paris, France). Transient Elastography (TE) is a novel, noninvasive and rapid bedside
method to assess liver fibrosis. During the first round of tests, TE was performed on the same
day as DBS and blood samples preparation for 38 of the 40 patients—and within a week for the
Anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots
PLOS ONE | https://doi.org/10.1371/journal.pone.0201629 July 31, 2018 3 / 13
two remaining patients. All TEs were performed on the day of DBS and blood sample prepara-
tion during the second round of samples.
Patients were diagnosed as having no or mild fibrosis when TE showed a median liver
stiffness 7.7 kPa, moderate fibrosis with stiffness 7.7 kPa-13.3 kPa, and as having cirrhosis
when the values were 13.3 kPa, in accordance with a previous large meta-analysis examining
correlations between fibrosis determined by liver biopsy and TE [34]. Liver stiffness measure-
ments were performed by physicians or nurses certified for the use of TE and with experience
from more than 50 examinations.
HCV-RNA determination and anti-HCV
HCV-RNA from DBS was extracted with either lysis buffer, protease K or plain, purified H2O.
Plain water turned out to give the best yield with our RNA extraction procedure. One DBS was
dissolved in 1mL H2O overnight. The samples were spun down at 10.800 G for 10 minutes.
We tested 500 and 100 μL of the supernatant, and 100 μL gave the best yield, whereas
500 μL resulted in some inhibition. Total RNA was isolated from 100 μL supernatant using
NucliSENS easyMAG Magnetic Silica (bioMe´rieux, Marcy l’Etoile, France). Detection and
quantification of viral nucleotide sequences were performed by In house real-time PCR using
molecular beacons on a Mx3005P Real-Time PCR System (Stratagene, La Jolla, USA). We also
tested our standard routine method Abbott RealTime HCV, but were not able to get meaning-
ful results. Antibodies against HCV (anti-HCV) were tested using our routine chemilumines-
cence assay (anti-HCV, Architect; Abbott Laboratories, Abbott Park, IL, USA) according to
the manufacturer’s recommendation only using supernatant instead of plasma.
IP-10 measurements
IP-10 levels in plasma and DBS samples were determined using ELISA, developed and opti-
mized for the monitoring of IP-10 in plasma and filter paper samples [26]. In brief, when used
for DBS’s, 2 discs of 5.5 mm are punched from the center of the DBS using a standard office
paper puncher (Impega, UK) and incubated with 100 μL assay buffer. Plasma samples were
diluted 1:4 in assay buffer. Plasma and DBS discs were incubated for 2 hours at room tempera-
ture (23 OC) and washed x 3, where after HRP-substrate (TMB One, Trichem) was added and
plates were revealed for 30 minutes before the color reaction was stopped with 100 μL H2SO4
and absorbance was read Concentrations were calculated using a standard curve with a linear
range from 2.5–600 pg/ml (Peprotec, USA). Plasma concentrations were corrected for the
dilution factor (multiplied x 5).
Statistics
We used Mann-Whitney or Kruskal-Wallis when appropriate to uncover association between
baseline parameters and IP-10. Linear regression was performed to show correlations between
plasma and DBS values and indicating cohesive r–and r2 values. Bland-Altman plots were used
to compare analytical methods. P values< 0.05 were considered statistically significant.
Results
In all we included 40 patients at baseline. The majorities of the patients were White, and
infected with GT 1. Overall baseline demographics and clinical variables for study patients can
be found in Table 1.
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HCV-RNA
Eleven patients were lost to follow up, initially leaving 69 parried samples from 40 patients
available. One DBS sample from baseline was incorrectly prepared and discarded. One DBS
sample and one plasma sample from two individual patients were false negative, reflected by
finding no HCV-RNA in patients known to be HCV-RNA positive. Exclusion of these three
samples (and the corresponding plasma or DBS sample) left 66 paired samples for analysis. Fig
1 shows a statistically significant correlation between log HCV-RNA concentration found in
plasma and log HCV-RNA deviated from DBS (P< 0.0001, R 0.6788, R2 0.4607).
This association remained when baseline samples and 6 months samples were analyzed sep-
arately (P < 0.0001, R 0.7526, R2 0.5664 and P< 0.0001, R 0.5754, R2 0.4562 respectively). The
HCV-RNA concentrations measured in DBS samples were systematically lower than the cor-
responding plasma levels, as illustrated by the Bland-Altman plot showing a bias of -3.041 log
HCV-RNA with SD of bias ± 0.6472 (Fig 2).
The plot also shows the difference being highest at the lower values.
Anti-HCV
Samples from 67 patients were available for anti-HCV determination. As all patients included
in the study were HCV-RNA positive, we expected all 67 samples to be anti-HCV positive. We
found 66 of the samples to be anti-HCV positive, and one sample to be (false) negative, trans-
lating to a sensitivity of 98.5%.
IP-10 and fibrosis stage
All 40 patients underwent a Fibroscan at baseline with a median TE-score of 6.1 kPa (25% per-
centile– 75% percentile, 4.9–10.2). Twentynine patients were available for follow up 6 months
later with a median score of 5.6 kPa (25% percentile– 75% percentile, 4.7–8.6). There was no
difference in the TE scores between baseline and 6 months follow up (P = 0.4736). Out of the
original 40 patients included, we were able to acquire subsequent TE-scores from 17 patients
performed 12–24 months after baseline with a median score of 7.6 kPa (25% percentile– 75%
percentile, 6.1–8.9). We found no significant difference in baseline IP-10 levels when compar-
ing patients with TE-scores above or below 7.7 kPa. (P = 0.267). Table 2 shows that patients
who showed any increase in TE score, between baseline and the six months follow up, did not
have higher baseline plasma IP-10 than patients who showed any decrease in TE score values
during the six months period (P = 0.266). Splitting patients up into groups, based on the
Table 1. Baseline characteristics for study patients.
Number of patients (n) 40
Gender (M/W) (n) 19/21
Age (years) (median, range) 55 (32–67)
Ethnicity (White /Hispanic /Asian) 35/2/3
TE-score (<7.7 kPa / >7.7 kPa—<13.3 kPa /  13.3 kPa) (n) 26/7/7
ALT (IU/L) (median, 25% - 75% percentile) 53 (34–95,5)
Genotype (1/2/3) (n) 25/5/10
HCV-RNA (IU/ml) (Mean, CI 95%) 687.000 (443.000–1.129.000)
Plasma IP-10 (pg/mL) (mean, CI 95%) 279 (92–366)
ALT levels could be obtained for 37/40 patients
https://doi.org/10.1371/journal.pone.0201629.t001
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baseline plasma IP-10 levels (<100 pg/ml, 150–300 pg/mL and > 300 pg/mL), did not yield
any significant differences in these patients’ TE scores at baseline (P = 0.231).
We examined if IP-10 concentrations at baseline correlated with HCV GT, ALT, TE-scores
and plasma HCV-RNA concentration (Table 2).
We found a significantly higher plasma IP-10 concentration in HCV GT 1 infected individ-
uals, as opposed to genotype-non-1 infected, but no other correlations.
Due to a strong suspicion of a technical problem in the analysis of the first seven DBS sam-
ples originating from baseline, (wrong buffer added), we excluded these samples. To allow
paired analysis the corresponding plasma samples were also excluded from the analysis. Two
DBS IP-10 samples failed at preparation at follow up, leaving 60 paired samples for further
analysis (the original 69 paired samples minus the 9 paired samples). When comparing IP-10
concentrations on DBS and paired plasma samples, we found a statistical significant correla-
tion (P< 0.0001, Persons r = 0.526, r2 = 0.2677). The corresponding Bland-Altman plot
Fig 1. Linear regression showing correlation between HCV-RNA Concentrations in plasma and DBS samples.
https://doi.org/10.1371/journal.pone.0201629.g001
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showed a bias of 219.9 pg/mL (SD ± 238.9) and some heteroscedasticity in the low concentra-
tion range as expected from lower volume available in the DBS samples. Fig 3 shows that we
found no statistical significant difference in plasma IP-10 levels between baseline and 6 months
follow-up.
Discussion
In this study we explored the potential of using DBS samples, sent by regular mail to determine
Anti-HCV antibodies, HCV-RNA and IP-10. We found statistically significant correlations
between log HCV-RNA and IP-10 concentration found in plasma and DBS, as well as success-
fully detected anti-HCV in 66/67 DBS samples.
Our findings on HCV-RNA are in line with previous studies [21, 35]. The difference in
HCV-RNA levels between plasma and DBS samples in this study were however lower than ear-
lier findings (1.5 log IU/mL and 2.27 log IU/mL). The difference could be due to HCV-RNA
Fig 2. Bland-Altman plot showing difference and average of samples derived from Log plasma HCV-RNA concentrations and Log DBS HCV-RNA
concentrations.
https://doi.org/10.1371/journal.pone.0201629.g002
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lost from the samples as they were transported by regular mail. Also, some of the difference
could be due to a lower number of patients in our study or variations in the methods used to
analyze the samples. Another reason could be the use of 903 Protein Saver™ cards, where FTA
cards would presumably have been more ideal for RNA analyses. However, as we used a single
heparin coated tube—known inhibitor of PCR, for extracting blood for both creating IP-10
plasma samples and later PCR, it is very likely that this is the main reason for the lower con-
centrations found.
Detection of HCV-RNA without quantification has also been shown in a number of previ-
ous studies [10–13, 15, 16, 19, 20], with sensitivity and specificity up to 90% and 100% with
corresponding PPV and NPV of 100% and 94% [13] The conjoined findings of correlation
between plasma and DBS samples, with- or without HCV-RNA quantification, indicate the
DBS samples can reliably be used to detect HCV-RNA. This report further adds that samples
can be mailed at ambient temperatures by regular postal services. Only one of the DBS sam-
ples, from a known HCV-infected patient, failed to show any HCV-RNA when tested. Regard-
ing anti-HCV we here confirm previous findings. [13–17, 20–22] Out of the 67 samples
available from HCV-RNA positive individuals, 66 were antigen positive. Corresponding to a
sensitivity of 98,5%.
In the era of pangenotypical DAA treatment, the need for quantifying HCV-RNA is hastily
diminishing, as HCV-RNA levels no longer have any role in treatment algorithms. From a
clinical point of view the information needed is thus: Is the patient HCV-RNA positive follow-
ing a positive anti-HCV test? Detection limits previously described for HCV-RNA in DBS
range from 150 [11]–to 2500 IU/mL [12], which is below the value in most patients with CHC
[36]. Thus, DBS testing represents an easy-to-use, stable test method to determine anti-HCV,
and HCV-RNA status in hard-to reach-settings, as well as in hard-to-reach populations.
Therefore, it could be a valuable tool for reaching the WHO goals for diagnosing 90% of HCV
infected individuals by 2030.
In this study we found no significant difference in baseline IP-10 levels and TE values,
though the relation between fibrosis and high IP-10 levels had been well documented [28, 31,
33, 37]. Regarding IP-10’s ability to predict fibrosis progression or decrease, we here only
examined 39 patients in a course of six months. And only a small number of test participants
had TE score values available 12–24 months after baseline. In the timespan we followed our
Table 2. Median plasma IP-10 concentrations at baseline in relation to genotype, ALT levels, TE-score levels- and dynamics and plasma HCV-RNA concentration.
Samples (n) Median [IP-10] (pg/mL) 25% - 75% percentile
(pg/mL)
P-Value
Genotype: GT 1 25 263 154–389 0.031
GT Non-1 15 141 116–287
ALT  ALT > 40 IU /mL 26 170 136.3–343 0.507
ALT < 40 IU /mL 11 250 125–351
TE score at baseline < 7.7 kPa 27 170 125–351 0.267
> 7.7 Kpa 13 278 160–341
Changes in TE score¤ Increase in TE score 14 304 153–394 0.266
Decrease in TE score 15 188 140–338
HCV-RNA # < 1 x 10 6 IU/mL 27 170 125–310 0.421
> 1 x 10 6 IU/mL 12 288 109–379
Three patients did not have available ALT data. ¤ Increase–or decrease in TE-Score value between measurements at baseline and at follow up 6 months after. Twenty-
nine patients completed follow up.
# One plasma HCV-RNA sample was incorrectly analyzed and excluded from analysis.
https://doi.org/10.1371/journal.pone.0201629.t002
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patient group we did not find any significant changes in fibrosis levels. However, it would be
interesting to follow up on fibrosis levels in 5–10 years, where significant changes in fibrosis
could have occurred. Only a small proportion of patients in our examination were cirrhotic at
baseline. Likewise, relatively few had advanced fibrosis. This, along with the limited number of
patients included, is a reasonable explanation why we did not find any correlation, and previ-
ous findings [28, 31, 33, 37] should therefore not be questioned on the basis of this study. In
any case, we here found a statistically significant association between IP-10 derived from
Fig 3. Showing no significant difference in plasma IP-10 levels in samples derived from baseline and at 6 months follow-up.
https://doi.org/10.1371/journal.pone.0201629.g003
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plasma, and IP-10 derived from DBS. However, the strength of the correlation was only mod-
erate, as reflected by the Pearson’s r of 0.526. Which does not represent satisfactory strength
for clinical use. The results should though be interpreted in the light of this being a small study
with only 40 patients included. It has previously been shown that IP-10 can be reliably mea-
sured in DBS [27, 28]. Here we did not include control samples which was not sent by mail.
Therefore, we could not evaluate what effect samples being sent had on IP-10 levels. Which
might have weakened the association we did find. This element should be added to future
studies.
A strength of this study is that we consecutively enrolled patients from our outpatient clinic
representing a standard cross section of Danish CHC patients, and this report is the first Dan-
ish study to successfully quantify HCV-RNA from DBS. In addition, this study is proof-of-
concept that it is possible to do so from DBS samples sent by regular postal service.
The study has some limitations that need to be addressed. First, the number of patients
included was relatively low. Secondly, we did not include any healthy controls making us
unable to calculate NPP and PPV values.
Another limitation is that we used blood from venous tubes to create the DBS which could
possibly yield some differences compared to DBS created from capillary blood, and that hepar-
inization of the blood probably was the main reason for the lower concentrations of HCV–
RNA found in blood compared to DBS samples. For the determination of fibrosis level, we
depended solely on TE, with a possible under- or over-estimation of intermittent levels of
fibrosis.
Conclusions
We successfully quantified HCV-RNA from DBS samples, dried at room temperature and sent
by regular mail. Concentrations of HCV-RNA from DBS were statistically significantly corre-
lated with plasma concentrations HCV-RNA. However, HCV-RNA concentrations obtained
from DBS were lower than the corresponding plasma values; a probable result of using heparin
coated test tubes. We found 66/67 (98.5%) of HCV-RNA positive patients to be anti-HCV pos-
itive in blood derived from filter paper, with only one false negative sample. We found that IP-
10 determined from DBS correlated statistically significantly with paired plasma samples. We
did however not find any correlation between IP-10 concentrations and liver fibrosis.
Over all, DBS could be a cost-effective easy-to-use and reliable alternative to standard tests
for the diagnosis of HCV infections.
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